HTD1801 (Berberine Ursodeoxycholate) shows potential as comprehensive therapy for MASLD/MASH and CKM syndrome

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory subtype, metabolic dysfunction-associated steatohepatitis (MASH), are increasingly prevalent and linked to obesity and type 2 diabetes mellitus (T2DM). These conditions are not isolated hepatic disorders but integral components of a broader cardiovascular–kidney–metabolic (CKM) syndrome, where metabolic dysfunction, chronic kidney disease, cardiovascular disease, and hepatic steatosis are interconnected. Current therapeutic guidelines offer effective treatments for individual components of CKM syndrome, yet no single agent comprehensively addresses the multifaceted metabolic, hepatic, and cardiorenal risks simultaneously, leaving a significant therapeutic gap.

This narrative review systematically evaluated existing human clinical evidence for six established therapeutic classes: metformin, GLP-1 receptor agonists, statins, SGLT2 inhibitors, PPAR agonists, and resmetirom. The authors compared their respective strengths and limitations across metabolic, hepatic, and cardiorenal outcomes relevant to MASLD/MASH and the broader CKM syndrome. The analysis aimed to identify current therapeutic gaps and assess the potential role of HTD1801 (Berberine Ursodeoxycholate), a novel combination agent, as a comprehensive, multi-target therapy capable of addressing these interconnected disease pathways.

The review highlighted that while agents like GLP-1 receptor agonists and SGLT2 inhibitors offer significant cardiovascular and renal benefits, and resmetirom targets hepatic fibrosis, no single existing therapy provides a comprehensive solution for all components of CKM syndrome alongside MASLD/MASH. Metformin primarily addresses glycemic control, statins target dyslipidemia, and PPAR agonists have shown mixed results with potential side effects. The authors concluded that the complex, interconnected nature of CKM syndrome necessitates a multi-targeted therapeutic approach. > The review identified HTD1801 (Berberine Ursodeoxycholate) as a promising candidate for combination therapy, given its dual components' established effects on metabolic, hepatic, and cardiovascular parameters, suggesting it could address multiple facets of MASLD/MASH and CKM syndrome simultaneously where other single agents fall short. This positions HTD1801 as a potential agent to overcome the limitations of current monotherapies by targeting diverse pathways involved in metabolic dysfunction, hepatic steatosis, and cardiorenal complications.